Related Experiment Video
Updated: Nov 19, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
The Relevance of the SH2 Domain for c-Src Functionality in Triple-Negative Breast Cancer Cells
Víctor Mayoral-Varo1, María Pilar Sánchez-Bailón1,2, Annarica Calcabrini1,3
1Instituto de Investigaciones Biomédicas A, Sols/Dpto. Bioquímica (CSIC/UAM), Arturo Duperier 4, 28029 Madrid, Spain.
Abstract:
The role of Src family kinases (SFKs) in human tumors has been always associated with tyrosine kinase activity and much less attention has been given to the SH2 and SH3 adapter domains. Here, we studied the role of the c-Src-SH2 domain in triple-negative breast cancer (TNBC). To this end, SUM159PT and MDA-MB-231 human cell lines were employed as model systems. These cells conditionally expressed, under tetracycline control (Tet-On system), a c-Src variant with point-inactivating mutation of the SH2 adapter domain (R175L). The expression of this mutant reduced the self-renewal capability of the enriched population of breast cancer stem cells (BCSCs), demonstrating the importance of the SH2 adapter domain of c-Src in the mammary gland carcinogenesis. In addition, the analysis of anchorage-independent growth, proliferation, migration, and invasiveness, all processes associated with tumorigenesis, showed that the SH2 domain of c-Src plays a very relevant role in their regulation. Furthermore, the transfection of two different aptamers directed to SH2-c-Src in both SUM159PT and MDA-MB-231 cells induced inhibition of their proliferation, migration, and invasiveness, strengthening the hypothesis that this domain is highly involved in TNBC tumorigenesis. Therefore, the SH2 domain of c-Src could be a promising therapeutic target and combined treatments with inhibitors of c-Src kinase enzymatic activity may represent a new therapeutic strategy for patients with TNBC, whose prognosis is currently very negative.
Insights
The SH2 domain of c-Src kinase is crucial for triple-negative breast cancer (TNBC) stem cell self-renewal and tumor progression. Targeting this domain offers a potential new therapeutic strategy for TNBC patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Src family kinases (SFKs) are implicated in human cancers, primarily through their tyrosine kinase activity.
- The roles of SFK adapter domains (SH2 and SH3) in tumorigenesis, particularly in triple-negative breast cancer (TNBC), are less understood.
- The c-Src SH2 domain's specific involvement in TNBC progression requires further investigation.
Purpose of the Study:
- To investigate the role of the c-Src SH2 adapter domain in triple-negative breast cancer (TNBC) pathogenesis.
- To evaluate the impact of inhibiting the c-Src SH2 domain on TNBC cell behavior and tumorigenic potential.
- To explore the c-Src SH2 domain as a potential therapeutic target for TNBC.
Main Methods:
- Utilized SUM159PT and MDA-MB-231 TNBC cell lines with a tetracycline-inducible system to express a c-Src variant with a mutated SH2 domain (R175L).
- Assessed the effects of SH2 domain mutation on breast cancer stem cell (BCSC) self-renewal, anchorage-independent growth, proliferation, migration, and invasiveness.
- Transfected cells with aptamers targeting the SH2 domain of c-Src to evaluate its functional role in TNBC progression.
Main Results:
- Expression of the c-Src SH2 domain mutant (R175L) significantly reduced BCSCs' self-renewal capability.
- The c-Src SH2 domain was found to play a critical role in regulating anchorage-independent growth, proliferation, migration, and invasiveness of TNBC cells.
- Aptamers targeting the SH2-c-Src domain inhibited proliferation, migration, and invasiveness in TNBC cell lines, confirming the domain's involvement in tumorigenesis.
Conclusions:
- The SH2 adapter domain of c-Src is essential for mammary gland carcinogenesis and TNBC progression.
- Inhibiting the c-Src SH2 domain demonstrates significant anti-tumor effects in vitro.
- The c-Src SH2 domain represents a promising therapeutic target, suggesting combined treatments with kinase inhibitors could improve outcomes for TNBC patients.
More Related Videos
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Nucleolus
Abnormal Proliferation
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...

